Captor Therapeutics (WAR:CTX) GF Score: 38/100 (As of Jul. 14, 2026) — 138% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CTX Captor Therapeutics SA WAR:CTX
38 GF Score
Price zł73.50
GF Value zł10.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Captor Therapeutics GF Score?

Captor Therapeutics WAR:CTX -2.52% 38 GF Score is 38 as of Jul. 14, 2026, which is 138% above its 10-year median of 16.00. GuruFocus rates WAR:CTX with a GF Score™ of 38/100 and a GF Value™ of zł10.13 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Captor Therapeutics has the GF Score of 38, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 1/10
5. Momentum Rank : 6/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Captor Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Captor Therapeutics  (WAR:CTX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Captor Therapeutics GF Score Related Terms

WAR:CTX vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Captor Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Captor Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's GF Score falls into.


WAR:CTX
38GF Score
Captor Therapeutics SA WAR:CTX
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 38 mean?
Captor Therapeutics (WAR:CTX) has a GF Score of 38 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Captor Therapeutics and its competitors. This is 138% above median its historical median of 16.00. Over the past decade, Captor Therapeutics' GF Score has ranged from 4.00 to 54.00.
Is Captor Therapeutics' GF Score too high?
Captor Therapeutics' current GF Score of 38 is 138% above median its 10-year median of 16.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 54.00. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' GF Score compare to VRTX and REGN?
Captor Therapeutics' GF Score of 38 can be compared against companies in the Biotechnology industry. Historically, Captor Therapeutics' own GF Score has ranged from 4.00 to 54.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current GF Score is 38, which is 138% above median its own 10-year median of 16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current GF Score is 38, which is 138% above median its 10-year median of 16.00. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current GF Score is 38 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued. The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13. GuruFocus considers Captor Therapeutics to be Significantly Overvalued.

Key valuation signals for WAR:CTX:

  • GF Score: 38 (138% above median its 10-year median of 16.00)
  • GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Captor Therapeutics Business Description

Address ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score

Get the complete analysis for WAR:CTX

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł73.50
Price
zł10.13
GF Value